

BIODELIVERY SCIENCES INTERNATIONAL INC  
Form SC 13G/A  
October 28, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

-----

SCHEDULE 13G

Information Statement pursuant to  
Rule 13d-1  
(Amendment No. 1)

-----

BioDelivery Sciences International, Inc.  
(Name of Issuer)

COMMON STOCK  
(Title of Class of Securities)

09060J106  
(CUSIP Number)

October 23, 2003  
(Date of event which requires filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

(Continued on following pages)

(Page 1 of 4)

Page 2 of 4

-----  
1. NAME OF REPORTING PERSON  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Stonestreet, L.P.

-----  
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)   
(b)

-----  
3. SEC USE ONLY

-----  
4. CITIZENSHIP OR PLACE OF ORGANIZATION

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G/A

Canada

-----  
NUMBER OF 5. SOLE VOTING POWER  
SHARES 336,600  
-----  
BENEFICIALLY 6. SHARED VOTING POWER  
OWNED BY None  
-----  
EACH 7. SOLE DISPOSITIVE POWER  
REPORTING 336,600  
-----  
PERSON 8. SHARED DISPOSITIVE POWER  
WITH None  
-----  
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
336,600  
-----  
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
 |  
-----  
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
4.8%  
-----  
12. TYPE OF REPORTING PERSON  
PN  
-----

Item 1(a). Name of Issuer.

BioDelivery Sciences International, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices.

185 South Orange Avenue, Administrative Building 4  
Newark, New Jersey 07103

Item 2(a). Names of Person Filing.

Stonestreet, L.P.

Item 2(b). Address of Principal Business Office, or if none, Residence.

The address of the principal business office of Stonestreet L.P. is:

260 Town Centre Blvd. Suite 201  
Markham, ON L3R 8H8 Canada

Item 2(c). Citizenship.

Stonestreet, L.P. is a Canadian Limited Partnership.

Item 2(d). Title of Class of Securities.

Common Stock

Item 2(e). CUSIP Number.

09060J106

Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b), check whether the person filing is a:

Not applicable. This statement is filed pursuant to Rule 13d-1(c)

Item 4. Ownership.

(a) Amount beneficially owned by reporting person: 336,600 shares of Common Stock of the Issuer.

(b) Percent of Class: 4.8% (based on 6,985,863 shares of Common Stock of the Issuer issued and outstanding as of August 14, 2003 as stated in the Issuer's Form 10-QSB filed on August 14, 2003).

(c) Number of shares as to which such person has:

(i) Sole power to direct the vote: 336,600 shares of Common Stock of the Issuer.

(ii) Shared power to vote or to direct the vote: None

(iii) Sole power to dispose or direct the disposition of the Common Stock: 336,600 shares of Common Stock of the Issuer.

(iv) Shared power to dispose or direct the disposition of: None

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [x].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for

Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form SC 13G/A

the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction which could have that purpose or effect.

Page 4 of 4

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: October 27, 2003

Stonestreet, L.P.

By: /s/ Michael Finkelstein  
Michael Finkelstein  
President